Epipox is a resource customized for epitope vaccine design against pathogenic orthopoxviruses.
The database is built upoen predicted T cell epitopes covering 124 proteins that are shared between the following
orthopoxvirus:
EPIPOX contains both CD4 and CD8 T cell epitopes that have been predicted using peptide-MHC I and II binding profiles, respectively .
In particular, we used 32 HLA I and 33 HLA-II specific matrices. Users can select single of combination of
HLA I molcules to retrieve the relevant T cell epitoptes. Here follow the list of HLA molecules in EPIPOX:
HLA I-restricted T cell epitopes
HLA-II restricted T cell epitopes
HLA I
Epitopes
HLA II
Epitopes
HLA_A0201
578
DRB1_0102
1000
HLA_A0202
581
DRB1_0301
982
HLA_A0203
598
DRB1_0311
988
HLA_A0205
589
DRB1_0401
975
HLA_A0206
592
DRB1_0402
988
HLA_A0207
570
DRB1_0404
978
HLA_A0301
577
DRB1_0405
977
HLA_A0101
589
DRB1_0406
944
HLA_A1101
575
DRB1_0407
934
HLA_A2301
601
DRB1_0408
969
HLA_A2402
601
DRB1_0410
977
HLA_A2403
601
DRB1_0801
1026
HLA_A2405
601
DRB1_0802
1006
HLA_A2407
601
DRB1_0804
1001
HLA_A3101
567
DRB1_0806
995
HLA_A3301
579
DRB1_0901
1022
HLA_A6801
578
DRB1_1101
1014
HLA_A6802
589
DRB1_1102
1008
HLA_B0702
595
DRB1_1103
973
HLA_B1501
583
DRB1_1104
1005
HLA_B1502
575
DRB1_1106
1005
HLA_B2705
561
DRB1_1201
955
HLA_B3501
595
DRB1_1301
1013
HLA_B4402
585
DRB1_1302
1042
HLA_B5101
573
DRB1_1304
994
HLA_B5301
599
DRB1_1305
1013
HLA_B5401
597
DRB1_1501
1018
HLA_B5801
601
DRB1_1502
1010
HLA_B0801
565
DRB3_0101
960
HLA_C0102
571
DRB3_0202
946
HLA_C0304
575
DRB4_0101
977
HLA_C0702
584
DRB5_0101
1034
DRB1_0101
993
T cell epitopes can be queried by any of the listed HLA molecules.
Supertypes are set of HLA molecules that have simililar peptide binding reperpertoires. In EPIPOX, we provide the
facility of identifying peptides that are predicted by 3 main supertypes
(A2, A3 and B7):
The alleles belogning to these supertypes are present in 88 % of the population regardless of their ething groups. Selecting promiscous peptides
restricted by these 3 supertypes facilitate maximizaing the population coverage of vaccines with minimum number
of peptides. For more details check Reche & Reche, NAR, 2005: W138-42